Clinical Trial Update: Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial compares cisplatin/pemetrexed with split-dose cisplatin/pemetrexed in non-small cell lung cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Universität Duisburg-Essen | Conditions: NSCLC | Phase 2 | Status: UNKNOWN